Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...
NCCN guidelines are evidence-informed, consensus-driven, and influential in US payer policies, with a focus on multidisciplinary representation and global adaptations. ESMO guidelines reduce care ...
Perioperative therapy has become a critical component in the management of resectable non–small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is ...
What Is Hyrnuo, and Why Does It Matter? Hyrnuo (sevabertinib) is a new oral medicine for adults with advanced nonsquamous non-small-cell lung cancer (NSCLC) carrying a specific genetic change known as ...
“Lung cancer, though common and serious, still has many misconceptions,” says Ian Bostock, MD, a thoracic surgeon at Miami Cancer Institute in Florida. “Clearing these myths helps patients and ...
This fact sheet explains how lung cancer is staged, and what each stage means. Lung cancer staging can be complex, but this fact sheet is intended for patient education. Our easy-to-read fact sheets ...
For stage 4 lung cancer treatment to be effective, it is essential that doctors perform accurate diagnosis before any therapy begins. They must determine the cancer's location and spread, as well as ...
Alecensa reduced death risk by 22% compared to Xalkori in advanced ALK-positive NSCLC, with a median OS of 81.1 months versus 54.2 months. The study was not powered for OS, resulting in ...
In his 20-year research career in Colorado, University of Colorado Cancer Center member D. Ross Camidge, MD, PhD, has published nearly 400 academic papers. But perhaps none have been so personal to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback